- Email: [email protected]
Guideline for Management of Febrile Neutropenia 2012 in Jsmo
Annals of Oncology 25 (Supplement 5): v42, 2014 doi:10.1093/annonc/mdu433.2
Poster Workshop (PWSF): ‘Febrile neutropenia’ PWSF1
8
GUIDELINE FOR MANAGEMENT OF FEBRILE NEUTROPENIA 2012 IN JSMO
Yasuhito Terui Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
The most serious adverse event in cancer patients who receive anti-neoplastic agents is febrile neutropenia(FN). The guideline on FN was published by the Japanese Society of Medical Oncology(JSMO)in 2012. The clinical guideline for management of patients with FN was also published by the Infectious Diseases Society of America. However, the dosage and administration of antimicrobial agents are not completely adapted for Japanese insurance coverage. Therefore, we decided to develop a clinical guideline for the management of FN in Japanese patients in 2012. In this study, we provide a general description of the guideline, including empiric treatment strategies, methicillin-resistant Staphylococcus aureus antibiotics in the initial treatment, treatment for severe FN, treatment for outpatients, duration of FN treatment, treatment after recovery from fever associated with neutropenia, and empiric treatment with anti-fungal drugs in patients with prolonged FN.
abstracts
Downloaded from http://annonc.oxfordjournals.org/ at Georgetown University on September 6, 2015
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Workshop (PWSF): ‘Febrile neutropenia’ PWSF1
8
GUIDELINE FOR MANAGEMENT OF FEBRILE NEUTROPENIA 2012 IN JSMO
Yasuhito Terui Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
The most serious adverse event in cancer patients who receive anti-neoplastic agents is febrile neutropenia(FN). The guideline on FN was published by the Japanese Society of Medical Oncology(JSMO)in 2012. The clinical guideline for management of patients with FN was also published by the Infectious Diseases Society of America. However, the dosage and administration of antimicrobial agents are not completely adapted for Japanese insurance coverage. Therefore, we decided to develop a clinical guideline for the management of FN in Japanese patients in 2012. In this study, we provide a general description of the guideline, including empiric treatment strategies, methicillin-resistant Staphylococcus aureus antibiotics in the initial treatment, treatment for severe FN, treatment for outpatients, duration of FN treatment, treatment after recovery from fever associated with neutropenia, and empiric treatment with anti-fungal drugs in patients with prolonged FN.
abstracts
Downloaded from http://annonc.oxfordjournals.org/ at Georgetown University on September 6, 2015
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].